Future Innovations

Intersect ENT, Inc. is dedicated to improving the quality of life for patients with ear, nose and throat conditions. We are developing a pipeline of steroid releasing implants designed to provide ENT physicians with options to treat patients across the continuum of care for chronic sinusitis less invasively and more cost effectively.

This webpage contains information on investigational devices and drugs. These products are limited by Federal (U.S.) law to investigational use. Intersect ENT makes no claims of safety or effectiveness of these unapproved investigational products. The intent of presenting this information is to convey research and development initiatives underway at Intersect ENT.

PROPEL® Contour:

The investigational PROPEL Contour, previously knowns as NOVA, steroid releasing implant is designed for placement in the peripheral sinus ostia. It is designed to prop sinus ostia open mechanically while delivering anti-inflammatory medication following surgical interventions, such as sinus surgery in the operating room or sinus dilation in the physician’s office. PROPEL Contour’s unique hourglass shape and lower profile is designed for placement in the smaller sinus openings, which may expand the applicable patient population for steroid releasing implants. PROPEL Contour has not been approved by the FDA.

To learn about the latest news regarding PROPEL Contour, please download our press release.

RESOLVE:

The investigational RESOLVE steroid releasing implant is designed to be placed during a physician office visit to provide a less invasive treatment option for patients with recurrent ethmoid sinus obstruction that would otherwise warrant revision surgery. The RESOLVE implant releases mometasone furoate directly into the sinus lining to target inflammation. It was designed with greater radial strength than the PROPEL products in order to dilate an obstructed sinus and releases steroid over a longer period of time to reduce inflammation. The RESOLVE implant is investigational and is not available for commercial use.
Four clinical studies of the RESOLVE implant have been conducted over the past five years, including a pilot study of 12 patients to evaluate feasibility of placement, a pharmacokinetic study of five patients, the RESOLVE randomized controlled trial of 100 patients evaluating both safety and efficacy, and the recently completed RESOLVE II Phase III randomized controlled trial of 300 patients.

To learn about the latest news regarding RESOLVE, please download our press release.